Evommune Brings Phase 2a Atopic Dermatitis Data to EADV
Evommune will present phase 2a atopic dermatitis data at the EADV Congress. The announcement names no effect size, endpoint, or cohort, so the readout's weight rests on the presentation itself.
Topic
Eadv
Topic
Eadv
Highlight Therapeutics Reports Positive Phase 2b Data for Intralesional BO-112 in Basal Cell Carcinoma
Positive Phase 2b topline results for intralesional BO-112 in localized basal cell carcinoma were presented as a late-breaker at…
BO-112 Hits Primary Endpoint in Phase 2b Basal Cell Carcinoma Trial
Phase 2b Spotlight-204 data presented at EADV show intralesional BO-112 produced visual and pathological response in 61% of BCC p…
Zumilokibart Hits EASI-75 Primary Endpoint in Phase 2 Atopic Dermatitis Trial
AbbVie's zumilokibart met its EASI-75 primary endpoint in the 346-patient Phase 2 APEX Part B study, with the mid-dose regimen ad…
AbbVie Brings 60 Dermatology Abstracts to 2026 EADV Congress
AbbVie will present 60 dermatology abstracts at the 2026 EADV Congress, one of the largest industry research footprints planned f…